A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of
investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin
therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be
enrolled in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer